National Organization to Examine Role of Invokana� in Diabetic Ketoacidosis
The�American Association of Clinical Endocrinologists�will hold a�conference in Dallas, TX this fall�to examine the potential link of SLGT2 Inhibitors such as Invokana�, Farxiga�, and Jardiance� to�diabetic ketoacidosis. �The conference is said to include scientists, doctors, and diabetes experts that have studied available information in an effort to provide recommendations to doctors and patients.
Invokana� was the first SLGT2 inhibitor approved by the FDA. �It is marketed as a cutting edge drug in the fight against Type 2 Diabetes. Invokana� is only approved to treat Type 2 Diabetes at this juncture. �However, Invokana� was a highly criticized approval by the FDA, some going so far as to call Invokana� a��Questionable New Diabetes Drug.�
FDA Warns of Possible Invokana� Link to Diabetic Ketoacidosis
The FDA released a safety warning in May, 2015 warning of the risk of diabetic ketoacidosis while on Invokana�, Farxiga�, Jardiance�, and the other SLGT2 Inhibitors. �While not a recall of these drugs, the warning was significant in that it noted 20 instances of diabetic ketoacidosis, ketoacidosis, or ketosis over a one year period. �All of these disorders are potentially deadly.
Atlanta, GA Invokana� Attorneys Taking�Lead in Warning Consumers
The Metro Atlanta, Georgia�Invokana� Attorneys�of The Parian Law Firm, LLC have spoken with people all over America about problems they attribute to�Invokana�, Farxiga�, and Jardiance�. �If you or a loved one has suffered any kidney problems or possible ketoacidosis while on the drugs, call our Atlanta Invokana� Attorneys�at (770) 727-5550 or chat online with us now. �You deserve to be informed.